RxDoctor Payments Data

Claudet Smith, MD

Internal Medicine · Beech Grove, INNPI 1124012729

Payments from drug & device makers

$1,686in general payments, 2019–2025

Across 41 payments — averaging $41.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$749
  • AstraZeneca$451
  • Novo Nordisk$268
  • Phathom Pharmaceuticals, Inc.$124
  • Amarin Pharma, Inc.$23
  • Astellas Pharma US Inc$20
  • plus $51 from 4 others

What the payments were for

  • Food & beverage$1,686100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,686 in reported general payments places this provider in the 80th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$82,672
Medicare patients
196
Services billed
1,041

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide94$123,219
MounjaroTirzepatide46$75,384
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$73,785
TrulicityDulaglutide31$65,177
JanuviaSitagliptin Phosphate44$45,954
Breo ElliptaFluticasone/Vilanterol45$26,992
MyrbetriqMirabegron19$24,533
EliquisApixaban18$17,541
TradjentaLinagliptin11$16,670
Spiriva HandihalerTiotropium Bromide11$16,382
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr25$15,704
LinzessLinaclotide19$14,485
SymbicortBudesonide/Formoterol Fumarate26$13,035
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog18$10,500
Lantus SolostarInsulin Glargine,hum.Rec.Anlog62$9,868

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$268$123,21994 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$749$116,482111 claims
MerckJanuvia$11$45,95444 claims
Astellas Pharma US IncMyrbetriq$20$24,53319 claims
AstraZenecaSymbicort, Farxiga$451$22,62939 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Beech Grove

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →